<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264208</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-51987</org_study_id>
    <secondary_id>PROS0098</secondary_id>
    <nct_id>NCT04264208</nct_id>
  </id_info>
  <brief_title>HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &amp;Multi Parametric MRI in Prostate Cancer</brief_title>
  <official_title>Evaluation of Patients With Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68-Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrei Iagaru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine whether the combination of imaging agents 68-Ga
      RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy
      than standard imaging or biopsy in patients with known prostate cancer (PC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

        1. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can detect additional cancers over
           mpMRI.

        2. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to
           treatment and predict progression free survival (PFS) at 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to Covid Issues
  </why_stopped>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">February 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>68-Ga-RM2 and 68-Ga-PSMA-11 PET/MRI can detect additional cancers over mpMRI</measure>
    <time_frame>60 months</time_frame>
    <description>Detection of PC lesions will be assessed by 68Ga PSMA 11 and 68Ga RM2 PET scans. The outcome is the number of participants without dispersion, by randomization schedule, for which an assessment of PET based PC lesions is successfully obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to treatment</measure>
    <time_frame>84 months</time_frame>
    <description>Therapeutic response to HDR will be assessed by 68Ga PSMA 11 and 68Ga RM2 PET scans. The outcome is the number of participants without dispersion, by randomization schedule, for which an assessment of PET based therapeutic response to HDR is successfully obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-free survival (PFS) will be assessed as survival without progression at 24 months. The outcome is reported as the number (without dispersion) of the participants alive without progression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-RM2 PET MRI/68Ga PMSA11 PET/MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo either 68Ga RM2 PET/MRI followed within 2 weeks by 68Ga PMSA11 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68Ga-PSMA-11 PET MRI/68Ga-RM2 PET MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo 68Ga PMSA11 PET/MRI followed within 2 weeks by 68Ga RM2 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Ga RM2.</intervention_name>
    <description>PET radiopharmaceutical</description>
    <arm_group_label>68Ga-PSMA-11 PET MRI/68Ga-RM2 PET MRI</arm_group_label>
    <arm_group_label>68Ga-RM2 PET MRI/68Ga PMSA11 PET/MRI</arm_group_label>
    <other_name>BAY86 7548</other_name>
    <other_name>68Ga DOTA Bombesin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Ga PSMA11</intervention_name>
    <description>PET radiopharmaceutical</description>
    <arm_group_label>68Ga-PSMA-11 PET MRI/68Ga-RM2 PET MRI</arm_group_label>
    <arm_group_label>68Ga-RM2 PET MRI/68Ga PMSA11 PET/MRI</arm_group_label>
    <other_name>DFKZ 11</other_name>
    <other_name>HBED CC PSMA</other_name>
    <other_name>Heidelberg compound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>PET/MR scanner by GE healthcare</description>
    <arm_group_label>68Ga-PSMA-11 PET MRI/68Ga-RM2 PET MRI</arm_group_label>
    <arm_group_label>68Ga-RM2 PET MRI/68Ga PMSA11 PET/MRI</arm_group_label>
    <other_name>PET/MR scanner</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18 years of age;

          -  Patients must be able to provide informed consent;

          -  Histologically proven low-grade or intermediate-grade prostate cancer (PC)

          -  Scheduled to undergo targeted local therapy (HDR brachytherapy).

        Exclusion Criteria:

          -  Inability to lie still for the entire imaging time;

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance;

          -  Metallic implants (contraindicated for MRI).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei H Iagaru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Professor of Radiology (Nuclear Medicine)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bombesin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

